";s:4:"text";s:6010:" Clinical Pharmacology, Pfizer Global R&D, Tokyo Laboratories, Pfizer Japan Inc., Tokyo, Japan,Clinical Sciences, Pfizer Global R&D, Sandwich, Kent, UK, andClinical Pharmacology, Pfizer Global R&D, Tokyo Laboratories, Pfizer Japan Inc., Tokyo, Japan,Clinical Sciences, Pfizer Global R&D, Sandwich, Kent, UK, andUse the link below to share a full-text version of this article with your friends and colleagues. A 10‐ml aliquot for fosfluconazole and FLCZ analysis was stored at − 70 °C within 30 min of completion of the collection.Plasma, urine and ultrafiltrate concentrations of fosfluconazole and FLCZ were determined at Maxxam Analytics Inc. (Mississauga, Ontario, Canada) using solid‐phase extraction of the analytes with separation by liquid chromatography, followed by atmospheric pressure ionization and tandem mass spectrometric detection [The overall method imprecision values of quality control samples (coefficient of variation) were less than 13.8% for fosfluconazole and 11.6% for FLCZ at the following concentrations: plasma and ultrafiltrates 0.6, 6 and 12 µg mlThe pharmacokinetic analysis of fosfluconazole and FLCZ plasma concentrations was performed by noncompartmental methods. 2004 Jun;60(4):247-53. doi: 10.1007/s00228-004-0764-x. One normal subject and three impaired subjects had ECG abnormalities postdose, or a more abnormal ECG compared with baseline, but most of these subjects had ECG abnormalities at screening and all abnormalities were considered by the investigator to be clinically insignificant.Subjects with hepatic impairment had lower mean plasma concentrations of fosfluconazole than normal subjects. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.Moderate Potential Hazard, Moderate plausibility.
injection. Select one or more newsletters to continue. Select one or more newsletters to continue.
This site needs JavaScript to work properly. Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. An additional 5 ml of blood was taken at 15 min and 1 h postdose for protein binding analysis. Plasma telmisartan concentrations may be increased in patients with obstructive biliary disease or hepatic impairment. Unable to load your collection due to an error Elderly No dose adjustment is necessary. Available for Android and iOS devices. Dose Adjustment for Hepatic Impairment Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. Dosage adjustments may be necessary. Br J Clin Pharmacol. 1 2 (See Special Populations under Absorption, in Pharmacokinetics.) The maximum observed plasma concentration (The total plasma clearance of unbound fosfluconazole (CLu) was calculated as CL/All observed or subjective adverse events were classified according to the Coding Symbol Thesaurus of Adverse Reaction Terms (COSTART).Blood and urine samples for laboratory safety tests were collected at prestudy screening, predose, 48 h postdose and at follow‐up.
Free PMC article Available for Android and iOS devices. patients with a creatinine clearance of <60 ml/min.